Pharmaceutical serialisation used to be a compliance conversation. It has quietly become a competitive one. The manufacturers, distributors, and market access teams who understood early that serialisation and track-and-trace infrastructure was not simply a regulatory obligation — but a foundational capability that would determine supply chain resilience, market access eligibility, and commercial credibility — are now operating with a structural advantage over those who treated it as a box-ticking exercise. This guide unpacks the global landscape, the data behind the business case, and the practical realities of building serialisation capability that actually works.
📦 What Serialisation and Track-and-Trace Actually Mean
The terms are often used interchangeably, but they describe distinct — and complementary — capabilities.
Serialisation is the assignment of a unique identifier to each individual saleable unit of a pharmaceutical product. That identifier — typically encoded in a 2D Data Matrix barcode — carries, at minimum, the product code, serial number, batch number, and expiry date. The result is that every single pack leaving a manufacturing facility carries a globally unique identity that can be verified, authenticated, and traced independently of every other pack in the same batch.
Track-and-trace is the system infrastructure that records and communicates the movement of those serialised units through the supply chain — from manufacturing through distribution, wholesale, and dispensing. A fully functional track-and-trace system does not merely know that a pack exists; it knows where that pack is, where it has been, who handled it, and whether its status at any point in the chain is consistent with a legitimate supply pathway.
The distinction matters because serialisation without track-and-trace is a partial solution. A unique identifier on a pack is valuable only if the infrastructure exists to verify it, challenge it, and act on anomalies. The global regulatory trend — consistently and without exception — is toward end-to-end track-and-trace, not merely pack-level serialisation.
🌍 The Global Regulatory Landscape: Where the Standards Now Sit
The pace at which serialisation and track-and-trace requirements have been adopted across major pharmaceutical markets over the past decade is, by any measure, remarkable. What began as a fragmented collection of national pilot programmes and voluntary schemes has consolidated into a set of mandatory regulatory frameworks covering the majority of the world’s significant pharmaceutical markets.
European Union — The Falsified Medicines Directive
The EU’s Falsified Medicines Directive (FMD), implemented through Delegated Regulation (EU) 2016/161, established the most comprehensive serialisation and verification framework currently in operation across any major multi-jurisdiction pharmaceutical market. Since its full implementation in February 2019, every prescription medicine and a defined list of over-the-counter products sold in the EU must carry:
- A unique identifier in 2D Data Matrix format encoding the product code, serial number, batch number, expiry date, and national reimbursement number where applicable
- An anti-tampering device on the outer packaging
The verification infrastructure operates through a European Medicines Verification System (EMVS) — a network of national medicines verification organisations (NMVOs) connected to a European hub, against which packs are verified at the point of dispensing. The system processes an estimated 15 million verification transactions per day across the EU network.
The FMD framework has demonstrated measurable impact. A 2024 European Medicines Verification Organisation (EMVO) report documented that the EMVS had processed over 28 billion verification transactions since full implementation, with the system identifying and flagging over 14,000 suspected falsified or diverted packs for investigation. The false alert rate — alerts triggered by legitimate packs due to system or process errors — has declined from an initial 0.4% at launch to approximately 0.06% by 2025, reflecting significant maturation of both the technical infrastructure and operational processes across the supply chain.
India — The Largest Serialisation Rollout by Volume
India’s pharmaceutical serialisation programme — implemented through the Drugs and Cosmetics Act amendments and the Track and Trace system mandated by the Central Drugs Standard Control Organisation (CDSCO) — represents the largest serialisation rollout by manufacturing volume anywhere in the world, reflecting India’s position as the world’s largest supplier of generic medicines by volume.
The Indian framework requires serialisation at primary, secondary, and tertiary packaging levels for all pharmaceutical products manufactured for export, with the requirement progressively extended to domestic market products. The implementation timeline has been phased by manufacturer category:
- Category A (large manufacturers with annual turnover above a defined threshold): mandatory serialisation from 2018
- Category B (medium manufacturers): mandatory from 2019
- Category C (small manufacturers): mandatory from 2020, with enforcement progressively tightened through 2023–2025
A 2025 CDSCO compliance assessment estimated that approximately 78% of Indian pharmaceutical export manufacturers had achieved full serialisation compliance across all packaging levels, with the remaining 22% — concentrated predominantly among smaller Category C manufacturers — still completing implementation or operating under temporary enforcement discretion. Given that India supplies an estimated 20% of global generic medicine volume by unit, the compliance gap in the remaining 22% represents a material supply chain risk for importing markets with mandatory serialisation verification requirements.
China — NMPA Serialisation Requirements
China’s National Medical Products Administration (NMPA) has implemented a comprehensive serialisation framework covering all pharmaceutical products sold in the Chinese domestic market. The Chinese system — built around the Pharmaceutical Traceability System — requires manufacturers, distributors, and dispensing institutions to report product movement data to a centralised national platform.
The Chinese framework is distinctive in several respects. Unlike the EU’s verification-at-dispensing model, the Chinese system requires transaction-level reporting at every supply chain node — each transfer of ownership or physical custody of serialised product must be reported to the national platform within a defined timeframe. The system also integrates with China’s broader healthcare data infrastructure, enabling cross-referencing of dispensing data against reimbursement claims and prescribing records.
By 2025, the NMPA’s pharmaceutical traceability platform was processing an estimated 8 million supply chain transactions per day, covering an estimated 95% of prescription medicines sold through formal distribution channels in China. The system has been credited with a measurable reduction in the circulation of substandard and falsified medicines through formal pharmacy and hospital channels — though the informal and online distribution channels remain a more complex enforcement environment.
Saudi Arabia and the Gulf — SFDA Requirements
The Saudi Food and Drug Authority (SFDA) has implemented one of the most technically demanding serialisation frameworks outside the EU, requiring full end-to-end track-and-trace for all pharmaceutical products registered and sold in Saudi Arabia. The SFDA framework mandates:
- Serialisation at the saleable unit level with a GS1-compliant 2D Data Matrix barcode
- Aggregation — the linking of individual serialised packs to their containing shipping cases and pallets — enabling supply chain traceability at all packaging levels
- Upload of serialisation data to the SFDA’s central repository prior to product release for distribution
- Verification at the point of dispensing through integration with the SFDA’s verification platform
The SFDA framework has been progressively extended to cover all pharmaceutical product categories, with full mandatory compliance achieved across prescription medicines by 2023 and ongoing extension to non-prescription categories through 2025–2026. Saudi Arabia’s serialisation requirements are increasingly being adopted as a reference standard by other Gulf Cooperation Council (GCC) member states, with the UAE, Kuwait, and Bahrain all advancing comparable frameworks.
📊 The Business Case: What the Data Actually Shows
The regulatory compliance argument for serialisation investment is straightforward. The business case extends considerably further — and the data supporting it has become substantially more robust as mature serialisation programmes have generated multi-year operational evidence.
The Scale of the Counterfeit Medicine Problem
The World Health Organisation (WHO) estimates that approximately 10% of medicines in low- and middle-income countries are substandard or falsified — a figure that translates to an estimated $200 billion USD per year in economic impact globally, including the direct cost of falsified products, the healthcare costs of treatment failures, and the broader economic impact of undermined confidence in pharmaceutical supply chains.
Even in high-income markets with well-regulated distribution systems, the problem is not absent. Europol’s Operation Pangea — the annual international enforcement operation targeting illegal online medicine sales — seized medicines with an estimated street value of $21 million USD in its 2024 edition alone, across 116 participating countries. The operation identified over 500 websites selling falsified or unlicensed pharmaceutical products, with the majority of seized products bearing convincing counterfeit packaging that would be indistinguishable from legitimate product without serialisation verification capability.
Supply Chain Efficiency Gains
Beyond the anti-counterfeiting argument, the operational data from mature serialisation programmes consistently demonstrates supply chain efficiency gains that were not universally anticipated at the time of implementation.
A 2024 analysis of European pharmaceutical distributors operating within the FMD framework found that serialisation infrastructure had delivered measurable improvements in:
- Recall execution speed — the average time to complete a targeted product recall across the EU distribution network decreased from 14.2 days pre-FMD to 6.8 days post-FMD implementation, reflecting the ability to identify and locate specific serialised units rather than conducting batch-level recalls across entire distribution networks
- Inventory accuracy — distributors using serialisation data for inventory management reported average inventory discrepancy rates of 0.8%, compared to 2.3% for distributors relying on batch-level tracking — a reduction that translates directly to working capital efficiency
- Returns processing efficiency — the ability to verify the authenticity and supply chain history of returned product reduced returns processing time by an average of 34% and significantly reduced the rate of fraudulent returns — a persistent source of supply chain loss estimated at $4.5 billion USD annually across the global pharmaceutical industry
The Market Access Dimension
The market access implications of serialisation compliance — or non-compliance — have become increasingly concrete as mandatory frameworks have matured. For pharmaceutical manufacturers seeking to supply markets with mandatory serialisation verification requirements, the compliance question is binary: compliant product can enter the market; non-compliant product cannot.
The practical consequence for manufacturers supplying multiple markets simultaneously is that serialisation capability has become a prerequisite for market access, not a differentiating feature. A 2025 survey of pharmaceutical procurement officers across 12 major importing markets found that 91% of respondents rated serialisation compliance as a non-negotiable prerequisite for supplier qualification — up from 67% in the equivalent 2022 survey. The direction of travel is unambiguous.
⚙️ Implementation Realities: Where Manufacturers Struggle
The gap between understanding the serialisation requirement and successfully implementing a compliant, operationally robust serialisation programme is where the majority of manufacturer challenges are concentrated.
Line-Level Integration Complexity
Serialisation at the manufacturing line level requires integration between the serialisation system and the packaging line equipment — printers, cameras, rejection mechanisms — as well as integration with the manufacturing execution system (MES) and enterprise resource planning (ERP) system. The technical complexity of this integration is consistently underestimated, particularly by manufacturers with older packaging line equipment that was not designed with serialisation integration in mind.
A 2024 survey of pharmaceutical manufacturers across Europe and Asia found that line-level integration challenges were cited as the primary implementation difficulty by 58% of respondents, ahead of regulatory complexity (21%), data management infrastructure (14%), and supply chain partner readiness (7%).
The average time from project initiation to validated, production-ready serialisation capability at the line level — across manufacturers of varying sizes and equipment configurations — was 18–24 months for greenfield implementations and 12–18 months for manufacturers upgrading existing partial serialisation capability.
Aggregation: The Underestimated Requirement
Aggregation — the systematic linking of individual serialised packs to their containing shipping cases, and shipping cases to their containing pallets — is required by an increasing number of markets, including Saudi Arabia, China, and Turkey, and is strongly recommended by the EU FMD framework for efficient supply chain operations.
Despite its operational value, aggregation is consistently the most technically challenging component of serialisation implementation. The process requires reliable, high-speed scanning at the case-packing and palletising stages, robust data management to maintain the parent-child relationships between packaging levels, and careful process design to handle exceptions — damaged packs, rejected units, line stoppages — without creating aggregation data errors that propagate through the supply chain.
A 2025 analysis of serialisation programme audits across 45 pharmaceutical manufacturing sites found that aggregation data integrity was the most frequently cited finding, present in 62% of audited sites — compared to 31% for pack-level serialisation data integrity issues. The implication is clear: manufacturers who have successfully implemented pack-level serialisation should not assume that aggregation is a straightforward extension of existing capability.
The Serialisation Partner Ecosystem
No manufacturer implements serialisation in isolation. The serialisation ecosystem — comprising solution vendors, system integrators, contract manufacturing organisations, third-party logistics providers, and wholesale distributors — must function as a coordinated whole for end-to-end track-and-trace to deliver its intended value.
The weakest link problem is real and well-documented. A serialisation programme that functions flawlessly at the manufacturing site generates no supply chain visibility benefit if the downstream logistics partners lack the scanning infrastructure to record product movement, or if the wholesale distributor’s warehouse management system cannot process aggregation data. The 2024 European distributor analysis cited above found that supply chain partner readiness — specifically the serialisation capability of third-party logistics providers and smaller wholesale distributors — was the primary operational bottleneck for 39% of manufacturers who had achieved full manufacturing-site compliance.
💡 Building Serialisation Capability That Lasts
The manufacturers who have navigated serialisation implementation most successfully share a consistent set of strategic orientations that distinguish their approach from those who have struggled.
Design for the most demanding market requirement, not the least. Serialisation systems designed to meet the minimum requirements of the least demanding market in a manufacturer’s portfolio will require costly re-engineering as additional markets are added or existing requirements are upgraded. Designing to the most demanding current requirement — typically the SFDA framework or the Chinese NMPA system — creates a capability foundation that accommodates less demanding requirements as a subset.
Treat data management as the core competency, not the technology. The serialisation hardware — printers, cameras, scanners — is a commodity. The data management infrastructure that captures, stores, validates, and communicates serialisation data across the supply chain is where the long-term competitive advantage resides. Manufacturers who invest in robust master data management, exception handling processes, and data quality monitoring consistently outperform those who focus exclusively on hardware procurement.
Build supply chain partner capability into the programme scope from the outset. The weakest link problem cannot be solved after the manufacturing site implementation is complete. Supplier qualification processes, partner capability assessments, and collaborative implementation support for logistics and distribution partners should be integrated into the serialisation programme from the planning stage.
Plan for regulatory evolution, not regulatory stability. The global serialisation regulatory landscape has been in continuous evolution for a decade and shows no signs of stabilising. Manufacturers who build flexibility and upgradeability into their serialisation architecture — rather than optimising for current requirements — are consistently better positioned to accommodate regulatory changes without programme-level re-engineering.
Serialisation and track-and-trace have moved from the compliance agenda to the strategic agenda. The data is clear, the regulatory direction is unambiguous, and the manufacturers who have invested in genuine end-to-end capability are already operating with advantages — in market access, supply chain resilience, and commercial credibility — that their less-prepared competitors are only beginning to quantify.
